Funding Early Innovation
is the strategic corporate venture capital arm of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, established in 2009. MS Ventures invests in companies that develop products and/ or technologies that could benefit patients in therapeutic areas relevant to our organization. The fund focuses primarily on early-stage investments.
Entrepreneur Partnership Program & MS Ventures Israel Bioincubator
Along with the €100 million MS Ventures fund, our team also manages the €30 million Entrepreneur Partnership Program fund established to support the creation of spin-offs, as well as the €10 million Israel Bioincubator Fund, focused on pre-seed and seed opportunities coming out of Israel.
What makes MS Ventures’ investment model successful?
As part of our investment process, we focus on assessing the potential commercial relevance of a new drug or a technology at a very early stage. We reconstruct the business plans of our companies top down, starting from the commercial proposition through to the experiments we need to undertake to drive our products there.
We believe that this philosophy induces our management teams to think harder and make better decisions about their product development, driven by the market and not just by their basic scientific hypothesis. Our goal is to optimally position the portfolio companies that offer their drugs or technologies to pharma for future strategic deals.